Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients
- Authors:
- Faruk Tas
- Senem Karabulut
- Didem Tastekin
- Derya Duranyildiz
View Affiliations
Affiliations: Department of Medical Oncology, Institute of Oncology, Istanbul University, Capa, Istanbul 34390, Turkey
- Published online on: February 19, 2016 https://doi.org/10.3892/br.2016.606
-
Pages:
489-492
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Protease-activated receptor-1 (PAR-1) has a significant role in the pathogenesis of various malignancies and its expression mainly affects the survivals of cancer patients. The aim of the present study was to determine the clinical significance of the serum concentrations of PAR‑1 in patients with gastric carcinoma. A total of 63 pathologically confirmed gastric cancer patients were enrolled in this study, with a median age of 62 years. Serum PAR‑1 concentrations were determined by the enzyme‑linked immunosorbent assay method and no significant difference in the baseline serum PAR‑1 concentrations was found between patients and normal controls (P=0.5). The investigated clinical variables, including patient age, gender, localization of lesion, histology, grade of pathology, disease stage and serum tumor markers (lactate dehydrogenase, carcinoembryonic antigen and carbohydrate antigen 19‑9) were not correlated with serum PAR‑1 levels (P>0.05). Furthermore, no association was identified between the serum PAR‑1 level and chemotherapy responsiveness (P=0.43). Serum PAR‑1 level also had no prognostic role for survival (P=0.27). In conclusion, the serum PAR-1 concentration has no diagnostic, predictive and prognostic values in gastric cancer patients.
View References
|
1
|
Fujimoto D, Hirono Y, Goi T, Katayama K
and Yamaguchi A: Prognostic value of protease-activated receptor-1
(PAR-1) and matrix metalloproteinase-1 (MMP-1) in gastric cancer.
Anticancer Res. 28(2A): 847–854. 2008.PubMed/NCBI
|
|
2
|
Liu L, Yan B, Yang Z, Zhang X, Gu Q and
Yue X: ncRuPAR inhibits gastric cancer progression by
down-regulating protease-activated receptor-1. Tumour Biol.
35:7821–7829. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fujimoto D, Hirono Y, Goi T, Katayama K,
Matsukawa S and Yamaguchi A: The activation of proteinase-activated
receptor-1 (PAR1) mediates gastric cancer cell proliferation and
invasion. BMC Cancer. 10:4432010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim SJ, Shin JY, Lee KD, Bae YK, Choi IJ,
Park SH and Chun KH: Galectin-3 facilitates cell motility in
gastric cancer by up-regulating protease-activated receptor-1
(PAR-1) and matrix metalloproteinase-1 (MMP-1). PLoS One.
6:e251032011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Henrikson KP, Salazar SL, Fenton JW II and
Pentecost BT: Role of thrombin receptor in breast cancer
invasiveness. Br J Cancer. 79:401–406. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rudroff C, Schafberg H, Nowak G, Weinel R,
Scheele J and Kaufmann R: Characterization of functional thrombin
receptors in human pancreatic tumor cells (MIA PACA-2). Pancreas.
16:189–194. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaufmann R, Schafberg H, Rudroff C and
Nowak G: Thrombin receptor activation results in calcium signaling
and protein kinase C-dependent stimulation of DNA synthesis in
HEp-2g laryngeal carcinoma cells. Cancer. 80:2068–2074. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ahn HS, Lee HJ, Hahn S, Kim WH, Lee KU,
Sano T, Edge SB and Yang HK: Evaluation of the seventh American
Joint Committee on Cancer/International Union Against Cancer
Classification of gastric adenocarcinoma in comparison with the
sixth classification. Cancer. 116:5592–5598. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
